Although targeted EGFR therapeutics such as TKIs are largely effective in the treatment of NSCLC with mutated EGFR, the development of resistance is a challenging issue for using TKI therapies in these patients3. This evidence concerns the gene EGFR and non-small cell lung carcinoma.